p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer

Pharmacogenetics. 1998 Dec;8(6):503-11. doi: 10.1097/00008571-199812000-00007.

Abstract

p53 mutation status was analysed in relation to DNA polymorphisms of GSTM1, CYP1A1 and CYP2E1 from 105 surgically resected non-small cell lung cancer cases. Demographic factors, smoking, occupation, family history, tumour histology, grade and stage were taken into account. p53 mutations, detected either directly by DNA sequencing (P = 0.04, adjusted for smoking) or indirectly by immunostaining (P = 0.06), were overrepresented among CYP1A1 variants. Mutations in exon 8 and transitions at CpG sites in the p53 gene were favoured in this subset. There was no relation between the individual gene polymorphisms or p53 mutations and disease-free survival by Kaplan-Meier analysis. The finding of excess CYP1A1 heterozygotes in individuals with p53 mutations after adjustment for smoking suggests that CYP1A1 activation contributes to lung cancer via p53 inactivation.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Cytochrome P-450 CYP1A1 / genetics*
  • Cytochrome P-450 CYP2E1 / genetics*
  • Disease-Free Survival
  • Genes, p53*
  • Glutathione Transferase / genetics*
  • Heterozygote
  • Homozygote
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics
  • Lung Neoplasms / surgery
  • Mutation*

Substances

  • Cytochrome P-450 CYP2E1
  • Cytochrome P-450 CYP1A1
  • Glutathione Transferase